News Sentiment

ENTA sentiment intelligence

Enanta Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.70 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-9.3% over one week, +15.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -9.3% Price reacting lower
Trend fit Trend inactive 15.1% over four weeks
Fair value 23.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 45
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 15
Market source 9
Business Wire 6
simplywall.st 5
Moomoo 3
Investing.com 3
Ad Hoc News 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 17
Regulatory and legal 7
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 63
Stock Titan Direct company coverage

[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event

Enanta Pharmaceuticals, Inc. (ENTA) reported via an 8-K filing that the United States Court of Appeals for the Federal Circuit affirmed a prior summary judgment ruling, invalidating Enanta's U.S. Patent No. 11,358,953. This patent was related to Pfizer Inc.'s COVID-19 antiviral,

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 22:10
Source
Stock Titan
IPWatchdog.com Direct company coverage

CAFC Affirms Enanta Coronavirus Patent Invalid for Lack of Written Description Support in Provisional Application

The U.S. Court of Appeals for the Federal Circuit (CAFC) has affirmed the invalidity of Enanta Pharmaceuticals, Inc.'s U.S. Patent 11,358,953 due to a lack of written description support in its provisional application. This decision means the patent cannot claim the earlier prior

Tone
Negative 29/100
Event
Market update
Published
23 Jun 2026 18:11
Source
IPWatchdog.com
Investing.com Direct company coverage

H.C. Wainwright reiterates Enanta stock rating on FDA alignment

H.C. Wainwright maintained a Buy rating and $20.00 price target for Enanta Pharmaceuticals (NASDAQ:ENTA) following the FDA's alignment on zelicapavir, which significantly reduces regulatory uncertainty for the RSV drug. Enanta also announced plans for late-stage clinical trials f

Tone
Positive 75/100
Event
Analyst action
Published
23 Jun 2026 12:11
Source
Investing.com
BioSpace Direct company coverage

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

Enanta Pharmaceuticals announced that its partner AbbVie received European Commission approval for MAVIRET® (glecaprevir/pibrentasvir) to treat acute Hepatitis C Virus (HCV) infection in adults and children aged 3 years and older. This makes MAVIRET the only EU-approved treatment

Tone
Positive 89/100
Event
Regulatory and legal
Published
23 Jun 2026 11:11
Source
BioSpace
Business Wire Direct company coverage

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET

The European Commission has approved MAVIRET (glecaprevir/pibrentasvir), developed by AbbVie with glecaprevir discovered by Enanta Pharmaceuticals, for treating acute Hepatitis C Virus (HCV) infection in adults and children aged 3 and older. This makes MAVIRET the only treatment

Tone
Positive 74/100
Event
Regulatory and legal
Published
23 Jun 2026 09:11
Source
Business Wire